Announcement on Shareholding Reduction Plan of Shareholder
Filed with SSE · · 6 pages · Chinese
Summary by 6ix AI
Shanghai Junshi Biosciences Co., Ltd. has announced a shareholding reduction plan by its shareholder, Shanghai Tanying Investment Partnership. The shareholder plans to reduce its holdings by a specified number of shares, representing a certain percentage of the company's total share capital. This reduction is due to liquidity needs and fund duration considerations, and will be executed through various trading methods. The announcement includes details on the shareholder's current holdings and the planned timeline for the reduction.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shanghai Junshi Biosciences Co., Ltd. on 6ix
Earlier from Shanghai Junshi Biosciences
- Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates
- Announcement on Results of Issuance of the 3rd Tranche of Sci-Tech Innovation Bonds in 2026
- Announcement on Results of Shareholding Reduction by Shareholder
- Indicative Announcement on Change in Equity of Shareholders Holding More Than 5% of the Shares Reaching 1% Threshold
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
Later from Shanghai Junshi Biosciences
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on Satisfaction of Exercise Conditions for the 1st Exercise Period of the Initial Grant under the 2025 A-Share Stock Option Incentive Plan and Cancellation of Certain Stock Options
- (688180)"Shanghai Junshi Biosciences Co., Ltd."Announcement on Voluntary Disclosure of Completion of First Patient Dosing in the Phase III Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma
- Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026
- Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Follow Shanghai Junshi Biosciences into a list and get an email when it puts out news.
Follow Shanghai Junshi Biosciences